According to the International Agency for Research on Cancer, the number of new cancer cases annually is expected to rise to 23.6 million by 2030 globally. Recently, cell line development and its applications are potential tools in oncology research. Cell lines are expected to be used to develop a new therapeutic pathway for various diseases including cancer and neurodegenerative diseases.
According to the latest research by Future Market Insights (FMI), Global Cell Line Development Market Its volume is expected to represent more than US$7,200 million, in value terms, by the end of 2028. The report on the Cellular Line Development Market anticipates significant growth potential with a compound annual growth rate of 7.2% until 2028.
The rapid increase in the prevalence of cancer and neurodegenerative diseases and the lack of an effective solution to these diseases has created the need for a more advanced and effective course of treatment. Corporations and government institutions are investing in research and development activities and also focusing more on cell line development in search of a new cellular pathway for developing new drugs. Increased spending on research and development of biosimilars from emerging biopharmaceutical companies will boost the market for developing cell lines.
Recently, contract research organizations are focusing on cell line development and cell line research activities. According to the National Institutes of Health (NIH), the estimated total federal spending on all types of stem cell line research for 2017 is $1.58 billion. In developing countries like India, the government supports the development of cell lines through national funding agencies like Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR) and Department of Science and Technology (DST).
Regenerative drugs are the next generation therapeutic solution, and cell line development or cell culture is a vital part of regenerative medicine. Increasing demand for regenerative drugs in cancer treatment would favorably affect the growth of the cell line development market during the forecast period.
Biopharmaceutical companies that are engaged in the development of a new drug line are expected to gain a promising revenue opportunity in the cell line development market.
Request the full table of contents for this report @ https://www.futuremarketinsights.com/toc/rep-gb-7566
Cellular line development sales analysis from 2013 to 2021 vs. market forecast for 2022 to 2028
The market capitalization of cell line development accounts for approximately 11.7% of the total drug discovery market of $37.3 million in 2021.
Compared with current mammalian expression systems, human cell lines have the ability to produce proteins similar to those manufactured naturally in the human body. This property is useful for advancements in protein therapies, and serves as a heavy driver towards the growth of the biopharmaceutical industry. The growth of these industries is increasing the demand for the cellular line development market. The advantage of using human cell lines for protein production is taken into account by the possibilities that the resulting recombinant protein will tolerate post-translational modifications that are consistent with endogenous human proteins.
The increasing burden of disease has prompted the development of new treatment pathways for diseases such as cancer and neurological disorders. The applications of hybridoma cell lines and recombinant cell lines in the development of therapeutic proteins have led to a growing demand for the cell line development market. Human cell lines, specifically stem cell lines, hold a potential position for treating various degenerative diseases, thus paving the way for new drug therapy in regenerative medicine.
Moreover, the increasing development and production of biosimilars, due to patent expiration of branded treatments, has positively affected the growth of the cell line development market. The global development of biotherapies with cell line development has promoted the development of a number of protein-based therapies, aiding the growth of highly expressing cell lines. These factors promote the expansion of the cell line development market on a global scale.
The global cellular line development market expanded by 6.1% CAGR during the past eight years from 2013 to 2021. The market is expected to expand at a significant growth rate over the next six years (2022-2028) at a compound annual growth rate of approximately 7.5%
Future Market Insights (FMI) has segmented the cell line development market based on product type, cell line source type, end user, cell line type, and region.
The product type segment in the cell line development market is segmented into media, reagents, equipment, and accessories. Reagents and media are required from incubation to maintaining cell lines. These products are expensive and have frequent use in cell culture or bioproduction. The reagents and media segment of the cell line development market is expected to witness significant growth in terms of revenue due to the rapidly increasing demand for cell culture and cell-based assays.
The cell line development market is categorized by cell line source into mammalian cells and non-mammalian cells. Mammalian cell line development is expected to witness significant growth in the overall cell line development market. This growth of the mammalian cell segment of the cell line development market is driven by the increased production of biological drugs that mammalian cells require. Increased antibody production is the main driving factor behind the growth of the mammalian cell line segment in the cell line development market.
Mammalian cell lines are used to synthesize therapeutic proteins through genetic construction and antibodies through viral infection. For example, Gaucher disease, a genetic disorder characterized by deficiency of the enzyme β-glucocerebrosidase and can be treated by Cerezyme which is a recombinant enzyme produced in mammalian cell lineages. Mammalian cell lines are also useful for the production of antibodies and other therapeutic agents such as specific binding proteins that can neutralize pathogens in the body. For example, within the cell line type segment of the cell line development market, recombinant cell line development is the most demanding cell line type due to the great application in biopharmaceutical production, protein interaction, gene activation, toxicity testing and drug screening.
The development of a recombinant cell line for increased application in drug toxicity testing is expected to enhance the growth of overall cell line development during the prediction period
The cell line development market will dominate in North America and Europe due to increased government funding in cell line development research and increased spending on developing biosimilars. The cell line development market in the Asia Pacific region is expected to grow at a high growth rate due to the increasing number of research institutions engaged in new biology and the fastest revenue growth in the overall cell line development market.
The Asia Pacific cell line development market is expected to witness an increase in the demand for biopharmaceuticals and renewable medicines and is expected to boost the growth of the cell line development market.
The FMI report tracks some of the major companies operating in the cellular line development market, such as Selexis SA, GE Healthcare, Corning Incorporated, Thermo Fischer Scientific, Inc. , American Type Culture Collection (ATCC), Lonza (Sartorius Stedim Biotech SA), Danaher Corporation, Merck KGaA, WuXi Biologics.
Major market segments covered in Cell Line Development Market Research
By product type:
- Detector and media
- Accessories and consumables
By source type:
- Mammalian cell line
- Non-mammalian cell line
By the end user:
- Biopharma companies
- Contract Research Organizations
- Academics and research institutes
- Biotechnology companies
By cell lines:
- Recombinant cell lines
- continuous cell lines
- primary cell lines
- North America
- Latin america
- CIS and Russia